During Monday’s trade, Shares of Arrowhead Research Corp (NASDAQ:ARWR), lost -2.08% to $6.08.
Arrowhead Research Corp, presented data at HEP DART 2015 showing that in chronically HBV-infected chimpanzees treated with ARC-520 in combination with nucleoside analogs, 7 of 9 (78%) exhibited signs of immune reactivation, which is likely a necessary step for achieving a functional cure of chronic HBV. One chimpanzee also exhibited an on-treatment therapeutic ALT flare and sustained virologic improvements 31 weeks off all treatment. ARC-520 is presently being studied in multiple Phase 2b global clinical trials. To reduce viral replication preceding to treatment with ARC-520, chimps were treated for 8-24 weeks with entecavir or in one case (chimp Michele) with entecavir and tenofovir. Following the NUC lead-in period, animals were administered ARC-520 intravenously at 4-week intervals (q4w). Dose levels were 2, 3, or 4 mg/kg ARC-520, together with maintenance doses of entecavir or entecavir and tenofovir. All 9 chimpanzees responded to ARC-520 with HBsAg reductions of 0.5 – 2.7 log10 at nadir, the greater reductions being in HBeAg positive chimps. HBsAg levels in all chimps continued to decrease with repeat dosing. Chimps were monitored for up to 31 weeks off all treatment.
For a more detailed due diligence report with analyst comments on Arrowhead Research Corp please follow the link. There is no cost obligation required to view analyst brief.
Shares of Weight Watchers International, Inc. (NYSE:WTW), declined -1.68% to $25.61, during its current trading session.
Weight Watchers International, introduces our breakthrough Beyond the Scale program, a holistic approach to a healthier, happier life that encompasses the evolving needs, mindsets and science around weight administration.
The new program comprises:
- New SmartPoints™ plan to make healthy eating simple: The new system delivers weight loss while using the latest nutritional science to go beyond both calories and the previous Weight Watchers Points Plus system. Smart Points is the plan Oprah Winfrey has been using to lose weight and eat healthier since she became a member in August.
- New fitness approach that fits a busy life: Members receive personalized activity aims and have access to the new Fit Break by Weight Watchers™ app, which assists turn moments of downtime into up time.
- A personalized program that serves each member’s lifestyle, aims and challenges: Based on an assessment, members get daily and weekly Smart Points targets, personalized activity aims and relevant content designed to assist find and fuel inner strength.
“We’re meeting members where they are recently, inspiring and guiding healthier choices not only to lose weight but realize benefits that go beyond just the number on the scale,” said Jim Chambers , President and CEO, Weight Watchers International, Inc. “Beyond the Scale delivers more ways than ever for you to personalize your program, define your success, and guide you on your road to healthier living.”
Finally, Shares of Bristol-Myers Squibb Con (NYSE:BMY), lost -0.49%, and is now trading at $68.51.
Bristol-Myers Squibb Company presented extended follow-up data and a pre-specified interim overall survival (OS) analysis of Empliciti in combination with Revlimid® (lenalidomide) and dexamethasone (ERd) in patients with relapsed or refractory multiple myeloma from ELOQUENT-2. The follow-up data demonstrated that Empliciti in combination with Rd had an improvement in progression-free survival (PFS) with a hazard ratio (HR) of 0.73 (95% CI: 0.60, 0.89; p=0.0014) as compared to Rd alone. This result was consistent with the improvement in PFS that was observed at the time of the primary analysis (HR 0.70 [95% CI: 0.57, 0.85; p = 0.0004]).
The Empliciti combination delayed the need for subsequent myeloma therapy by a median of one year contrast to Rd alone. A pre-specified interim analysis of OS found a positive trend favoring the Empliciti combination as compared to Rd alone (HR 0.77; [{95% CI: 0.61, 0.97; 98.6% CI: 0.58, 1.03}; p=0.0257]), though at the time of the interim analysis the OS endpoint had not reached the pre-determined threshold for statistical significance. Patients will continue to be followed for survival. Updated safety and tolerability data were consistent with previous findings. Common Grade 3 or 4 adverse events comprised neutropenia (26%), anemia (15%), fatigue (9%), and diarrhea (5%).
These data from ELOQUENT-2, a randomized, open-label, Phase 3 study (Abstract #28) were presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, FL.
“The Empliciti extended follow-up results provide physicians with additional insight into the potential benefit this new treatment may offer patients with relapsed or refractory multiple myeloma,” said Paul G. Richardson, M.D., Clinical Program Leader and Director of Clinical Research, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute. “Empliciti represents a new approach in multiple myeloma treatment of directly activating the body’s immune system, and it is very encouraging to see these data demonstrate the efficacy benefit persisted in some patients up to three years, allowing patients to live longer without experiencing disease progression.”